Rigel Run Down By Another Failure
This article was originally published in Scrip
Executive Summary
Rigel Pharmaceuticals's pipeline looked precarious last June when its partner AstraZeneca dropped rights to their rheumatoid arthritis program; now the company's pipeline looks downright devastating after the biotechnology company announced yet another failure.